



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

February 28, 2020

Via E-mail

Mr. Bo Kruse

Executive Vice President and Chief Financial Officer

Y-mAbs Therapeutics, Inc.

230 Park Avenue, Suite 3350

New York, New York 10169

**Re: Y-mAbs Therapeutics, Inc.  
Form 8-K  
Exhibit No. 10.1 Sublicense Agreement  
Filed December 19, 2019  
File No. 001-38650**

Dear Mr. Kruse:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance